SANGAMO THERAPEUTICS, INC cotiza a 0.15 USD y tiene una capitalización bursátil de $62M. En los últimos 12 meses ha facturado $35M con un margen de flujo de caja libre del -246.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which…
| Periodo | 2026-10 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.08 | $-0.07 | $-0.11 |
| Estimado | $-0.07 | $-0.07 | $-0.05 | $-0.10 |
| Sorpresa | — | -14.3% | -40.0% | -10.0% |
| Métrica | SGMOQ | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -306.5% | -38.6% | -267.9% |
| Net Margin | -310.8% | -33.6% | -277.3% |
| FCF Margin | -246.0% | -13.9% | -232.2% |
| ROE | — | -40.4% | — |
| ROA | -205.8% | -32.0% | -173.8% |
| Current Ratio | 0.84 | 2.84 | -2.00 |
| Debt / Equity | — | 0.28 | — |